公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
1998 | Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives | WEI-CHU CHIE ; Li C.-Y.; CHIUN-SHENG HUANG ; KING-JEN CHANG ; MEN-LUH YEN ; Lin R.-S. | International Journal of Cancer | 35 | | |
2022 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | Geyer, C E; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; CHIUN-SHENG HUANG ; et al., | Annals of oncology : official journal of the European Society for Medical Oncology | 96 | 67 | |
1999 | p27 expression as a prognostic factor of breast cancer in Taiwan | Chu J.-S.; CHIUN-SHENG HUANG ; KING-JEN CHANG | Cancer Letters | 18 | 12 | |
2004 | p53 overexpression and mutation in metaplastic carcinoma of the breast: Genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components | HUANG-CHUN LIEN ; CHUNG-WU LIN ; TSUI-LIEN MAO ; SUNG-HSIN KUO ; Hsiao C.-H.; CHIUN-SHENG HUANG | Journal of Pathology | 67 | 63 | |
2018 | Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial | Bardia A.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG ; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. | Journal of Clinical Oncology | 39 | 37 | |
2020 | Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors | Dawood S.; Chiu J.W.-Y.; CHIUN-SHENG HUANG ; Nag S.; Sookprasert A.; Yap Y.-S.; Md Yusof M. | Current Medical Research and Opinion | 5 | 5 | |
2022 | Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4 | Xu, Binghe; Hu, Xichun; Li, Wei; Sun, Tao; Shen, Kunwei; Wang, Shusen; Cheng, Ying; Zhang, Qingyuan; Cui, Shude; Tong, Zhongsheng; Geng, Cuizhi; Song, Erwei; CHIUN-SHENG HUANG ; et al., | European journal of cancer (Oxford, England : 1990) | 22 | 13 | |
2014 | The partner's insecure attachment, depression and psychological well-being as predictors of diurnal cortisol patterns for breast cancer survivors and their spouses | FEI-HSIU HSIAO ; Jow G.-M.; WEN-HUNG KUO ; CHIUN-SHENG HUANG ; Lai Y.-M.; Liu Y.-F.; KING-JEN CHANG | Stress | 9 | 9 | |
2022 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study | Gianni, L; CHIUN-SHENG HUANG ; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, E M; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G | Annals of oncology : official journal of the European Society for Medical Oncology | 118 | 83 | |
2020 | Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer | Conte P.; Schneeweiss A.; Loibl S.; Mamounas E.P.; von Minckwitz G.; Mano M.S.; Untch M.; CHIUN-SHENG HUANG ; Wolmark N.; Rastogi P.; D’Hondt V.; Redondo A.; Stamatovic L.; Bonnefoi H.; Castro-Salguero H.; Fischer H.H.; Wahl T.; Song C.; Boulet T.; Trask P.; Geyer C.E.; Jr. | Cancer | 16 | 12 | |
2013 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial | Azim H.A.; Agbor-Tarh D.; Bradbury I.; Dinh P.; Baselga J.; Di Cosimo S.; Greger Jr. J.G.; Smith I.; Jackisch C.; Kim S.-B.; Aktas B.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.K.; Dreosti L.; Eidtmann H.; Piccart M.; De Azambuja E. | Journal of Clinical Oncology | 48 | 47 | |
2020 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial | Cortes J.; Cescon D.W.; Rugo H.S.; Nowecki Z.; Im S.-A.; Yusof M.M.; Gallardo C.; Lipatov O.; Barrios C.H.; Holgado E.; Iwata H.; Masuda N.; Otero M.T.; Gokmen E.; Loi S.; Guo Z.; Zhao J.; Aktan G.; Karantza V.; Schmid P.; Luis F.; Gonzalo G.A.; Diego K.; Ruben K.; Matias M.; Mirta V.; Sally B.-H.; Stephen B.; Philip C.; Sherene L.; Dhanusha S.; Andrea G.; Donatienne T.; Carlos B.; Leandro B.; Fabiano C.; Ruffo D.F.J.; Roberto H.; Domicio Carvalho L.; Fernando Cezar Toniazzi L.; Roberto Odebrecht R.; Antonio Orlando S.N.; Felipe S.; David C.; Danielle C.; Cristiano F.; Xinni S.; Joanne Y.; Alejandro A.; Carlos G.; Claudio S.; Cesar S.; Eduardo Y.; Alvaro G.D.; Jesus S.; Petra H.; Zdenek K.; Bohuslav M.; Katarina P.; Jana P.; Vesna G.; Erik J.; Jeanette J.; Soren L.; Tamas L.; Herve B.; Isabelle D.; Anthony G.; Anne-Claire H.-B.; Luis T.; Jens-Uwe B.; Peter F.; Dirk F.; Nadia H.; Jens H.; Anna K.F.D.S.; Christian K.; Sibylle L.; Diana L.; Tjoung-Won P.-S.; Raquel Von S.; Pauline W.; Louis C.; Ava K.; Kai Cheong Roger N.; Peter A.; Tibor C.; Zsuzsanna K.; Laszlo L.; Karoly M.; Gabor R.; John C.; Catherine K.; Seamus O.R.; Saverio C.; Antonietta D.A.; Enrico R.; Tomoyuki A.; Takaaki F.; Kenichi I.; Takashi I.; Yoshinori I.; Tsutomu I.; Hiroji I.; Yoshimasa K.; Koji M.; Yasuo M.; Hirofumi M.; Seigo N.; Naoki N.; Shoichiro O.; Akihiko O.; Yasuaki S.; Eiji S.; Masato T.; Yuko T.; Kenji T.; Koichiro T.; Junichiro W.; Naohito Y.; Yutaka Y.; Teruo Y.; Anita B.; Mastura M.Y.; Angel G.V.; Alejandro J.R.; Jorge M.R.; Flavia M.-V.; Jessica R.C.; Karin B.; Vivianne T.-H.; David P.; Ewa C.; Ewa N.-Z.; Zbigniew N.; Barbara R.; Joanna S.; Cezary S.; Rafal T.; Bogdan Z.; Alexander A.; Natalia F.; Oleg L.; Andrey M.; Vladimir M.; Guzel M.; Jin Hee A.; Seock-Ah I.; Keun Seok L.; Kwong Hwa P.; Yeon Hee P.; Begona B.D.L.H.; Javier C.; Josefina C.J.; Luis D.L.C.M.; Jose G.S.; Maria G.; Esther H.; Esther Z.A.; Chien-Ting L.; Mei-Ching L.; Chiun-Sheng H.; Chao-Jung T.; Ling-Ming T.; Cagatay A.; Gul B.; Irfan C.; Erhan G.; Seyda G.; Nil M.M.; Mustafa O.; Ozgur O.; Sinan Y.; Steve C.; Janine G.; Iain M.; Peter S.; Nicholas T.; Mark T.; Christopher T.; Duncan W.; Hryhoriy A.; Oleksandr B.; Igor B.; Oleksii K.; Olena K.; Hanna K.; Anna K.; Iurii L.; Alla N.; Natalya O.; Olga P.; Andrii R.; Sergii S.; Yaroslav S.; Dmytro T.; Grygorii U.; Ihor V.; Sibel B.; Madhu C.; Michael C.; Patrick C.; Scott C.; Jennifer D.; Keerthi G.; Jeffrey H.; Kent H.; William I.; Randa L.; Janice L.; Raul M.; Susan M.; Rita N.; Ira O.; Coral O.; Timothy P.; Amit P.; Brian P.; Hope R.; Irina R.; Michael S.; Robert S.; Michael S.; Laura S.; Bradley S.; Michaela T.; Frances V.-A.; KEYNOTE-355 Investigators; CHIUN-SHENG HUANG | The Lancet | 878 | 815 | |
2022 | Perceived Causes of Cancer and Corresponding Behavioral Changes: A Qualitative Study on Breast Cancer Survivors in Taiwan | Niu, Jasmine; DUAN-RUNG CHEN ; Chiao Lo ; SHAO-YI CHENG ; CHIUN-SHENG HUANG | Cancer Control : Journal of the Moffitt Cancer Center | 0 | 0 | |
2015 | Personalization of loco-regional care for primary breast cancer patients (part 1) | Toi M.; Winer E.P.; Benson J.R.; Inamoto T.; Forbes J.F.; Von Minckwitz G.; Robertson J.F.; Grobmyer S.R.; Jatoi I.; Sasano H.; Kunkler I.; Ho A.Y.; Yamauchi C.; Chow L.W.; CHIUN-SHENG HUANG ; Han W.; Noguchi S.; Pegram M.D.; Yamauchi H.; Lee E.-S.; Larionov A.A.; Bevilacqua J.L.; Yoshimura M.; Sugie T.; Yamauchi A.; Krop I.E.; Noh D.Y.; Klimberg V.S.; 2014 Kyoto Breast Cancer Consensus Conference | Future Oncology | 5 | 5 | |
2015 | Personalization of loco-regional care for primary breast cancer patients (part 2) | Toi M.; Winer E.P.; Benson J.R.; Inamoto T.; Forbes J.F.; Von Minckwitz G.; Robertson J.F.; Grobmyer S.R.; Jatoi I.; Sasano H.; Kunkler I.; Ho A.Y.; Yamauchi C.; Chow L.W.; CHIUN-SHENG HUANG ; Han W.; Noguchi S.; Pegram M.D.; Yamauchi H.; Lee E.-S.; Larionov A.A.; Bevilacqua J.L.; Yoshimura M.; Sugie T.; Yamauchi A.; Krop I.E.; Noh D.Y.; Klimberg V.S. | Future Oncology | 3 | 3 | |
2021 | Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study | Shao Z.; Tseng L.-M.; CHIUN-SHENG HUANG ; Pang D.; Yang Y.; Li W.; Liao N.; Geng C.; Zhang Q.; Xu B.; Liu D.; Kwong A.; et al (continued in the appendix) | Japanese journal of clinical oncology | 2 | 1 | |
1998 | Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma | Yu A.L.; Uttenreuther-Fischer M.M.; CHIUN-SHENG HUANG ; Tsui C.C.; Gillies S.D.; Reisfeld R.A.; Kung F.H. | Journal of Clinical Oncology | 223 | 180 | |
2011 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer | YEN-SHEN LU ; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO ; CHIUN-SHENG HUANG | Cancer Chemotherapy and Pharmacology | 10 | 8 | |
2002 | Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma | CHIUN HSU ; CHIUN-SHENG HUANG ; Chao T.-Y.; YEN-SHEN LU ; Bu C.-F.; Chen M.M.; KING-JEN CHANG ; ANN-LII CHENG | Cancer | 12 | 11 | |
2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |